Biosearch Life signs an agreement with Angelini pharmaceutical, S.A. for the marketing in Hereditum ® Lc40 Spain for the treatment of mastitis in lactating women

Biosearch Life signs an agreement with Angelini pharmaceutical, S.A. for the marketing in Hereditum ® Lc40 Spain for the treatment of mastitis in lactating women

– a preventive and curative treatment to mastitis – inflammation of the chest associated with the breastfeeding-a disease that is the leading medical cause of the early abandonment of the practice recommended by the who is

-strains of the range Hereditum ®, the only ones from breast milk, have been selected among hundreds for their excellent skills and its scientifically proven beneficial effects

Madrid, may of 2012- Biosearch Life, biotechnology company of reference in the world of healthy ingredients, has announced the signing of a license and agreement exclusive distribution with Angelini pharmaceutical marketing in the Spanish market of Hereditum ® Lactobacillus Fermentum Lc40 oriented preventive and curative treatment of mastitis in lactating women.

we are very pleased by the signing of this agreement with Angelini pharmaceutical and insurance that the fruit of this collaboration will be an invaluable help for nursing mothers and health of their infants. During recent years we have worked very hard on this project, so it makes us especially excited to move it to the market and offer another innovative solution designed to maintain and improve the health of people ”, says Jose Mª Roset, Director General of Biosearch Life. Collaboration with Angelini will help us to further consolidate our position in the market. This agreement represents a step more in our commitment to develop innovative ingredients intended for the area of health ”

Hereditum ®

Hereditum ® is the brand name associated with the range of grains Biosearch Life strains isolated obtained from breast milk, and protected by various patents globally.

in addition to their difference in origin, that the grains strains available in the market do not originate from human milk, strains of the Hereditum ® range have been selected among hundreds by their excellent skills and its scientifically proven beneficial effects.

the unique origin of Hereditum ® makes these products, not only excellent candidates for use in child nutrition, but that their extraordinary grains properties and technological versatility ensures high performance and functionality in numerous applications for the pharmaceutical market and functional food.

mastitis

mastitis is an inflammation of the chest associated with breastfeeding which is the first medical cause of the early abandonment of the practice (which is recommended by the World Health Organization exclusively for at least the first six months of life of the newborn, for its benefits on health in the short and long term).

up to fifteen per cent of women who choose to breastfeed their babies come to suffer from mastitis, a disease that appears during breastfeeding and that produces inflammation of the breast, almost always of infection and severe headaches accompanied. The treatment carried out regularly, taking antibiotics, shows cash in a small percentage of treated cases and automatically imply the abandonment of breastfeeding.

Hereditum ® Lactobacillus Fermentum Lc40 ECA not only eliminates the painful symptoms associated with mastitis but that, in addition to ensuring a minimum level of recurrence by its natural origin, lets continue with lactation, with all the benefits that this entails for the health of the mother and the newborn.

Angelini pharmaceutical

the Angelini Group produces and markets products for the health and well-being. The Angelini group is characterized by research, development and marketing of those products that meet the needs of the market, promoting constant supply of new opportunities for the pharmaceutical sector and the well-being of people.

supply of Angelini is broad and covers different needs in the field of the treatment and prevention.

, after almost a century of dedication to the pharmaceutical industry, the Angelini group is currently present in more than 50 countries, where it occupies a privileged position in different therapeutic areas: ophthalmology, Central nervous system, locomotive apparatus, Gynecology, fertility and Pediatrics. participates also in the OTC market.

the Angelini group is present in Spain through its Angelini pharmaceutical S.A. Division from 1978.

Biosearch Life

Biosearch Life is a leader in biotechnology with innovative vocation at the global level. The society has a presence in the national and international markets in the pharmaceutical, dietetic and sectors of functional food, where it is present with its value proposition in services and products that revolve around the concept of healthy living.

Biosearch Life designs ingredients bioactive allowing to develop drugs, dietary supplements and functional foods affecting, among others, in improving cardiovascular health, weight control, health joint, cognitive development, immune system and cell aging.

Biosearch Life provides complete solutions to clients in more than 30 countries for those looking for maximum satisfaction with solutions to measure and a solid portfolio of more than 200 products grouped in lipids, probiotics and natural extracts. The company is an international reference in the production and marketing of functional fats (Omega 3), has a portfolio of unique market grains strains by their origin from breast milk, and offers a full range of plant extracts. In addition, since its inception, fruit of his research work has developed numerous worldwide patents.

Biosearch Life sells its products under three brand names: Eupoly ® for your products based on Omega 3; Hereditum ® for their grains strains; and Exxentia ® for the line of vegetable extracts.